文献速递脑血管病

致残性与非致残性轻型前循环血管闭塞卒中的再灌注治疗

Reperfusion Treatments in Disabling Versus Nondisabling Mild Stroke due to Anterior Circulation Vessel Occlusion.
PubMed 文献 · Stroke · 2023-02-27

基于SITS-ISTR注册研究(2015-2021年),纳入1459例发病4.5小时内、NIHSS≤5分且存在颅内颈内动脉、M1、A1-2或M2-3闭塞的急性缺血性卒中患者,比较致残性与非致残性轻型血管闭塞患者再灌注治疗的安全性和有效性。倾向性评分匹配后每组336例,两组在3个月改良Rankin量表0-1分、0-2分、早期神经功能改善及安全性结局上均无显著差异。作者认为两组可采用相似的急性治疗策略,但需随机对照数据明确最佳再灌注治疗方案。

要点

  • 致残性与非致残性轻型EVT-tVO患者再灌注治疗后3个月功能结局无显著差异。
  • 两组症状性颅内出血和3个月死亡等安全性结局相似,均无显著差异。
  • 作者建议两组采用相似的急性治疗策略,但需随机数据进一步明确。

核心结论

  • 致残性与非致残性轻型EVT-tVO患者接受急性再灌注治疗后安全性和有效性结局相似,作者建议两组采用相似的急性治疗方法,并指出需随机数据明确最佳再灌注治疗。

研究设计与样本

  • 基于SITS-ISTR注册研究,纳入2015-2021年发病4.5小时内、NIHSS≤5分且存在颅内颈内动脉、M1、A1-2或M2-3闭塞的连续急性缺血性卒中患者。
  • 共纳入1459例患者,经倾向性评分匹配后致残性与非致残性EVT-tVO组各336例。

主要发现

  • 匹配后3个月改良Rankin量表0-1分:致残性组67.4% vs 非致残性组71.5%,P=0.336,无显著差异。
  • 匹配后3个月改良Rankin量表0-2分:致残性组77.1% vs 非致残性组77.6%,P=0.895,无显著差异。
  • 匹配后早期神经功能改善:致残性组38.3% vs 非致残性组44.4%,P=0.132,无显著差异。
  • 匹配后非出血性早期神经功能恶化:致残性组8.5% vs 非致残性组8.0%,P=0.830;任何颅内出血或蛛网膜下腔出血:12.5% vs 13.3%,P=0.792;症状性颅内出血:2.6% vs 3.4%,P=0.598;3个月死亡:9.8% vs 9.2%,P=0.844,均无显著差异。

关键数值与推荐

  • 轻型EVT-tVO定义为NIHSS评分≤5分且存在颅内颈内动脉、M1、A1-2或M2-3闭塞。
  • 治疗时间窗为发病4.5小时内。
  • 致残性与非致残性采用可获得的定义进行区分。

临床怎么用

  • 作者认为,对于致残性与非致残性轻型EVT-tVO患者,可采用相似的急性再灌注治疗方法。
  • 作者指出需随机数据明确轻型EVT-tVO的最佳再灌注治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefit of distinguishing between disabling versus nondisabling deficit in mild acute ischemic stroke due to endovascular thrombectomy-targetable vessel occlusion (EVT-tVO; including anterior circulation large and medium-vessel occlusion) is unknown. We compared safety and efficacy of acute reperfusion treatments in disabling versus nondisabling mild EVT-tVO. METHODS: From the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register, we included consecutive acute ischemic stroke patients (2015-2021) treated within 4.5 hours, with full NIHSS items availability and score ≤5, evidence of intracranial internal carotid artery, M1, A1-2, or M2-3 occlusion. After propensity score matching, we compared efficacy (3-month modified Rankin Scale score of 0-1, modified Rankin Scale score of 0-2, and early neurological improvement) and safety (nonhemorrhagic early neurological deterioration, any intracerebral or subarachnoid hemorrhage, symptomatic intracranial hemorrhage, and death at 3-month) outcomes in disabling versus nondisabling patients-adopting an available definition. RESULTS: We included 1459 patients. Propensity score matched analysis of disabling versus nondisabling EVT-tVO (n=336 per group) found no significant differences in efficacy (modified Rankin Scale score 0-1: 67.4% versus 71.5%, P=0.336; modified Rankin Scale score 0-2: 77.1% versus 77.6%, P=0.895; early neurological improvement: 38.3% versus 44.4%, P=0.132) and safety (nonhemorrhagic early neurological deterioration: 8.5% versus 8.0%, P=0.830; any intracerebral hemorrhage or subarachnoid hemorrhage: 12.5% versus 13.3%, P=0.792; symptomatic intracranial hemorrhage: 2.6% versus 3.4%, P=0.598; and 3-month death: 9.8% versus 9.2%, P=0.844) outcomes. CONCLUSIONS: We found similar safety and efficacy outcomes after acute reperfusion treatment in disabling versus nondisabling mild EVT-tVO; our findings suggest to adopt similar acute treatment approaches in the 2 groups. Randomized data are needed to clarify the best reperfusion treatment in mild EVT-tVO.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Schwarz G, Cascio Rizzo A, Matusevicius M, et al. Reperfusion Treatments in Disabling Versus Nondisabling Mild Stroke due to Anterior Circulation Vessel Occlusion. Stroke. 2023. PMID: 36848431. doi:10.1161/STROKEAHA.122.041772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。